- Pay-Per-Patient Pricing Available to Reduce Start-Up Barriers forCancer Centers
Advertisement
Nucletron, a knowledge-based leader in radiation oncology, and AdvancedRadiation Therapy (ART) announced today an exclusive global, strategicpartnership to offer the AccuBoost(R) system with the microSelectron(R) high-dose rate (HDR) brachytherapy afterloader treatment delivery solution for thetreatment of breast cancer. The partnership will enable clinicians all overthe world to deliver boost brachytherapy as part of the whole breastirradiation procedure, providing a superior treatment option with theultimate goal of improving clinical outcome.
Advertisement
The partnership offers radiation oncology centers the opportunity toimplement ART's innovative technology in image-guided HDR breastbrachytherapy on a pay-per-patient pricing model, along with a fullcomplement of Nucletron's treatment planning, treatment delivery, training,licensing, reimbursement, and customized service support. ART's expansion ofAccuBoost technology through its global partnership with Nucletron willfurther reduce the barriers to adoption of brachytherapy for cancer centerspreviously deterred by the initial start-up costs usually associated withimplementing a breast brachytherapy program.
"We are thrilled to partner with ART and expand the availability andutilization of HDR brachytherapy globally," said Jos Lamers, chief executiveofficer for Nucletron. "Using Nucletron's microSelectron Digital afterloaderto deliver AccuBoost technology further reduces the financial, operational,and clinical barriers many cancer centers encounter in providingbrachytherapy to their patients. In conjunction with this announcement,Nucletron is offering a pay-per-patient pricing model for centers bundlingthe AccuBoost treatment option with their new HDR brachytherapy program,allowing these centers to pay for the service when the boost treatment isdelivered, providing a more attractive financing model while delivering moretreatment options to their patients."
"Advanced Radiation Therapy is pleased to partner with Nucletron," statedPiran Sioshansi, Ph.D., president and chief executive officer of ART. "Ourgoal is to make the AccuBoost treatment option available to as many women aspossible, all over the world. The market reach and expertise in HDRbrachytherapy provided by Nucletron will help us realize this goal. Togetherwe can accelerate the introduction of this new, non-invasive, image-guidedprocedure to more clinical sites worldwide."
Clinical reports indicate that patients with early stage breast cancerhave the best outcomes when the breast conserving lumpectomy procedure iscombined with a full course of whole breast irradiation and partial breastboost dose. ART's AccuBoost combines a mammography procedure for real-timeimage guidance to accurately target the boost dose, and precise dose deliveryby Nucletron's microSelectron family of HDR afterloaders. By increasing theaccuracy of the dose-targeting and reducing the unintentional exposure tohealthy tissue, including the heart, lungs, and skin, AccuBoost is expectedto improve patient outcomes, minimizes side effects and result in a bettercosmetic results.
Representatives will be on hand to discuss this strategic partnership atthe American Brachytherapy Society's School of Breast Brachytherapy andBrachytherapy Physics in San Antonio, TX on February 12-13, and the 2009 ACROAnnual Meeting in Las Vegas, NV on February 26-27.
About Nucletron
Nucletron is a knowledge-based leader in Radiation Oncology, working withclinical teams to realize innovative solutions that improve patient care.Nucletron strives to offer the best possible choice of radiation modalitiesthrough integrated products, software and services. Critical to the Nucletronphilosophy is the establishment of close working relationships withindividual clinical teams - reconfiguring traditional boundaries betweencustomer and solution provider. Many Nucletron employees have clinicalexperience delivering oncology care, providing an in-depth understanding ofthe complex needs of clinicians. For more information, visithttp://www.nucletron.com.
About Advanced Radiation Therapy (ART)
ART is a women's health company dedicated to the advancement of partialbreast irradiation with the goal of reducing the cancer recurrence rate andminimizing radiation related complications. ART's AccuBoost system combinesreal-time, image-guidance with non-invasive, high-dose rate brachytherapy todeliver a focused dose to the lumpectomy site. The AccuBoost technology isbased on the premise that the best method to immobilize, image and targetbreast tissue is via mammography. As such, AccuBoost gives the clinicians thecomfort and confidence to "see what you treat and treat what you see" andsignificantly reduces the unintentional exposure to the patient's heart andlungs. For more information, visit http://www.AccuBoost.com.
SOURCE Nucletron B V
